【肝病】慢性乙型肝炎核苷（酸）类似物经治患者抗病毒治疗专家共识：2016年更新.pdf

· 527 ·中华实验和临床感染病杂志 (电子版) 2016年10月 第10卷 第5期 Chin J Exp Clin Infect Dis (Electronic Edition), October 2016, Vol.10, No.5 ·指南 · 慢性乙型肝炎核苷（酸）类似物经治患者 抗病毒治疗专家共识： 2016年更新 ¤ŸY˜É‚（Ö） ?型??宝?子化丸?宝E??准 【摘要】 多数慢性乙型肝炎患者经过核苷（酸）类似物抗病毒治疗后，远期预后可获得显著改 善，但仍有部分患者在治疗后发生原发无应答、应答不佳以及复发。为规范慢性乙型肝炎经治患者的 再治疗， 2013年我们组织国内部分专家讨论并形成了《慢性乙型肝炎核苷（酸）类似物经治患者抗病 毒治疗专家共识》。近 3年来，符合循证医学原则的研究数据不断增加，对慢性乙型肝炎核苷（酸） 类似物（ NAs）经治患者抗病毒治疗的认识亦有提高；因此，我们再次组织专家对相关最新资料进行 分析整理，形成本共识的 2016年更新。 【关键词】肝炎，乙型，慢性；核苷（酸）类似物；原发无应答；应答不佳；复发 Expert consensus on antiviral therapy in nucleos(t)ide analogues experienced patients with chronic hepatitis B: 2016 update Committee of experts on antiviral therapy in nucleos(t)ide analogues experienced patients with chronic hepatitis B 【Abstract】 Nucleos(t)ide analogues (NAs) are potent in inhibiting hepatitis B virus replication and improving prognosis in most patients with chronic hepatitis B. But primary non-response, suboptimal response, and relapse may occur in some patients. To optimize the management of NAs experienced patients, the committee for antiviral therapy in nucleos(t)ide analogues experienced patients with chronic hepatitis B published the consensus on antiviral therapy in nucleos(t)ide analogues experienced patients with chronic hepatitis B in 2013. With more and more evidence in management of these patients in the late 3 years, the committee of antiviral therapy in nucleos(t)ide analogues experienced patients with chronic hepatitis B updated the consensus to provide the updated recommendation for management NAs experienced patients. 【Key words】Chronic hepatitis B; Nucleos(t)ide analogues; Primary non-response; Suboptimal